Association Study of Polymorphism in CYP3A5 Gene with Bladder Cancer

• Main Authors: m bakhtiari tajar, Kh Onsory, p shadpoor, m zafarmand
• Format: Article
• Language: fas
• Published: Yasuj University Of Medical Sciences 2015-09-01
• Series: Armaghane Danesh Bimonthly Journal
• Subjects: CYP3A5 gene; polymorphism; Bladder cancer; PCR-RFLP.
• Online Access: http://armaghanj.yums.ac.ir/browse.php?a_code=A-10-156-2&slc_lang=en&sid=1

Aims and objectives: The environmental procarcinogen hypothesis of tumour pathogenesis proposes that many carcinogens require metabolic activation by drug metabolizing enzymes to form the proximate carcinogen. CYP3A enzyme catalyzes the conversion of numerous numbers of xenobiotics including carcinogens and drugs and it is involved in metabolic pathways of activation of procarcinogens and/or inactivation of carcinogens during the tumorigenic processes. CYP3A5 is expressed polymorphically in human liver, but consistently in lung, colon, and kidney. An allelic variant of A to G (A6986G) transition causes CYP3A5*3 variant and this polymorphic expression confers low CYP3A5 protein expression as a result of improper mRNA splicing and reduced translation of a functional protein. The purpose of this study was to analysis the frequency of mutations in CYP3A5 gene and to determine the role of its polymorphisms in bladder cancer patients. Methods: For this purpose, PCR-RFLP analysis of the gene was on 113 bladder cancer patients and same number of age-matched controls admitted to Hashemi Nezhad Hospital was performed. Then the data was analyzed using the computer software SPSS for windows (version 19). Results: The incidence of CYP3A5*3 allele was more in patients and control group compared with the wild type (CYP3A5*1). It was 79.6% and 75.2% in patients and controls respectively which indicated that the mutant allele of CYP3A5*3 was more in the studied population with an OR of 1.837 (95% CI=0.975-3.460, P= 0.62). Also there was found that the frequency of both alleles were high in female compared with male. Conclusions: There was no significant association between the risk of bladder cancer for individuals carrying the CYP3A5*3 genotype.